e-learning
resources
Copenhagen 2005
Monday 19.09.2005
Atypical bacteria, fungal and parasitic infections of the lung
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Treatment of chronic necrotizing pulmonary aspergillosis (CNPA) with micafungin (MCFG)
D. Tokunaga, N. Takayanagi, K. Kurashima, Y. Sugita, M. Kanazawa (Kohnan, Moroyama, Japan)
Source:
Annual Congress 2005 - Atypical bacteria, fungal and parasitic infections of the lung
Session:
Atypical bacteria, fungal and parasitic infections of the lung
Session type:
Thematic Poster Session
Number:
2617
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Tokunaga, N. Takayanagi, K. Kurashima, Y. Sugita, M. Kanazawa (Kohnan, Moroyama, Japan). Treatment of chronic necrotizing pulmonary aspergillosis (CNPA) with micafungin (MCFG). Eur Respir J 2005; 26: Suppl. 49, 2617
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Treatment of chronic pulmonary aspergillosis by voriconazole compared with micafungin
Source: Annual Congress 2009 - Complications of respiratory infections: impact of comorbidities and infections caused by Aspergillus
Year: 2009
Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma
Source: Eur Respir J 2011; 37: 865-872
Year: 2011
Retrospective study on the combined use of voriconazole and prednisolone in the treatment of acute allergic bronchopulmonary aspergillosis (ABPA).
Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma
Year: 2019
Caspofungin to treat invasive pulmonary aspergillosis in sarcoidosis
Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections
Year: 2012
Clinical features of chronic pulmonary aspergillosis treated with voriconazole in patients with chronic respiratory disease
Source: Annual Congress 2008 - Biomarkers and antibiotic treatment of exacerbations of COPD
Year: 2008
Allergic/invasive pulmonary aspergillosis in CGD (chronic granulomatous disease) patients
Source: Annual Congress 2009 - Host factors in paediatric bacterial respiratory infection
Year: 2009
Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients
Source: Eur Respir J 2001 Jan 01;19(4):743-755
Year: 2002
Caspofungin pulses for CPA (chronic pulmonary aspergillosis): A retrospective study
Source: International Congress 2016 – Severe respiratory infections in the intensive care unit and pleural and fungal infections
Year: 2016
Omalizumab and voriconazole in allergic broncopulmonary aspergillosis (A case series)
Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E
Year: 2011
Voriconazole treatment in CF patients with ABPA and/or invasive aspergillosis
Source: Annual Congress 2010 - New aspects of cystic fibrosis
Year: 2010
Chronic pulmonary aspergillosis complicating sarcoidosis
Source: Eur Respir J, 49 (6) 1602396; 10.1183/13993003.02396-2016
Year: 2017
Clinical features of pulmonary aspergillosis in patients with chronic fibrosing interstitial pneumonia
Source: Annual Congress 2010 - Different patterns of diffuse parenchymal lung disease
Year: 2010
Nontuberculous mycobacterial disease and Aspergillus-related lung disease in bronchiectasis
Source: Eur Respir J 2006; 28: 352-357
Year: 2006
Clinical features of chronic pulmonary aspergillosis in patients with interstitial pneumonia
Source: Annual Congress 2010 - Bronchiectasis and respiratory infections caused by Pseudomonas
Year: 2010
Prolonged oral corticosteroid therapy in allergic bronchopulmonary aspergillosis (ABPA) treatment does not increase pseudomonas aeruginosa risk
Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment
Year: 2015
Breakthrough invasive pulmonary aspergillosis (IPA) in patients receiving posaconazole prophylaxis (PPxis)
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
Efficacy and tolerability of voriconazole in the treatment of pulmonary aspergillosis
Source: Eur Respir J 2007; 30: Suppl. 51, 301s
Year: 2007
Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide
Source: Eur Respir J 2002; 20: 127-133
Year: 2002
PET‘s importance in chronic pulmonary aspergillosis
Source: Eur Respir J 2006; 28: Suppl. 50, 560s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept